Company profile: Brahms
1.1 - Company Overview
Company description
- Provider of biomarker-based diagnostic test procedures and automated immunoanalyzers (KRYPTOR) using TRACE technology to improve diagnosis and treatment of life-threatening illnesses. Offerings include biomarkers for prenatal screening, oncology and thyroid disease management; sFlt-1/PlGF for preeclampsia risk; CgA II for neuroendocrine tumor monitoring; TRAK human for Graves’ disease; and Copeptin proAVP for water balance and acute myocardial infarction.
Products and services
- B·R·A·H·M·S Biomarkers: Patented biomarker repertoire for prenatal screening, oncology evaluation, and thyroid disease management, furnishing precise analytes for targeted diagnostic applications
- B·R·A·H·M·S KRYPTOR Instruments: TRACE-based automated immunoanalyzers for various diagnostic tests, including prenatal and oncology screenings, produced under the B·R·A·H·M·S KRYPTOR brand
- B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System: Pregnancy-specific KRYPTOR test system that assesses the risk of preeclampsia in pregnant women using sFlt-1/PlGF markers for targeted risk evaluation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Brahms
Sangamo Therapeutics
HQ: United States
Website
- Description: Provider of engineered DNA-binding protein-based therapeutics, conducting clinical trials of gene and cell therapy candidates including: giroctocogene fitelparvovec for hemophilia A; ST-920 for Fabry disease; TX200 for patients undergoing a kidney transplant; SB-525/giroctocogene fitelparvovec (Phase 1/2); and BIVV003 ex vivo cell therapy for severe sickle cell disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sangamo Therapeutics company profile →
HTG Molecular
HQ: United States
Website
- Description: Provider of assays and reagent systems for gene expression analysis, including the HTG Transcriptome Panel for full transcriptome profiling to support drug and companion diagnostic discovery; HTG EpiEdgeSeq for RNA modification profiling; and a Drug Discovery Engine and pipeline targeting RNA‑Modifying Proteins across oncology, autoimmune, neurodegenerative, and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HTG Molecular company profile →
Lifecode Health
HQ: United States
Website
- Description: Provider of patient-specific molecular information to improve patient lives, amid the growing accessibility of molecular tumor profiling and the challenge of analyzing and interpreting the expanding genomic and therapeutic data from next-generation sequencing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lifecode Health company profile →
Verinata Health
HQ: United States
Website
- Description: Provider of non-invasive tests for early identification of fetal chromosomal abnormalities, using proprietary technologies to enhance maternal and fetal health and reduce anxiety associated with the current multi-step process and false positives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verinata Health company profile →
Decode Genetics
HQ: Iceland
Website
- Description: Provider of biopharmaceutical diagnostic tests for gene variant detection, using population studies to identify human genes linked to common diseases and applying findings to guide candidate drug development; has discovered key genetic risk factors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Decode Genetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Brahms
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Brahms
2.2 - Growth funds investing in similar companies to Brahms
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Brahms
4.2 - Public trading comparable groups for Brahms
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →